This content is from: Patents

“Far-reaching impacts” of Federal Circuit ruling on ANDA personal jurisdiction

The Federal Circuit ruling in Acorda v Mylan and AstraZeneca v Mylan gives branded pharmaceutical companies more flexibility in their choice of where to file suit against generics

Get Free Access to read more …

To read the full article, activate your free trial.

Get Free Access
  • Unlimited articles for one week
  • No commitments; no payment details required
  • Featuring IP strategy, copyright, patents, trademark and more!

Are you a Managing IP subscriber? Simply login here.

Related